Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
FDA Legislation Regulation

User Fee Draft Suggests Congressional Wariness Of Trump Budget

  • Analysis

Executive Summary

Discussion draft includes US FDA negotiated user fee amounts well short of the total in recent Trump budget outline.

You may also be interested in...



First Draft FDA User Fee Bill Is Squeaky Clean

House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.

PDUFA First: Fees To Support Device Center Staff

To enhance combination product reviews, drug fee revenue will pay for related positions in CDRH.

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.

Table

View full table

Topics

Tags:
FDA Legislation Regulation
Latest Headlines

Japan’s CEA Scheme: How It Works And Impact So Far

US FDA’s Califf: Payers Should Ask How They Can Help Answer Clinical Research Questions

EU Pharma Wants Regulators’ Help To Simplify Digital Endpoints Landscape

Partnerships Are Key To Sustainable mRNA Vaccine Production In LMICs

See All
UsernamePublicRestriction

Register

PS120443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By